NSI-189 CAS # 1270138-40-3

NSI-189 CAS # 1270138-40-3

Category:

Neuralstem, Inc. is testing an experimental potential antidepressant called NSI-189 for the treatment of major depressive disorder (MDD), as well as cognitive decline and neurodegeneration.

While statistically significant changes were reported on a number of secondary depression and cognition endpoints, a phase II clinical trial for MDD failed to reach the primary depression endpoint (MADRS) in July 2017.

The behavior of the compound was discovered by phenotypic screening of a library of 10,269 compounds in order to find compounds that stimulated neurogenesis in vitro. The compound’s goal was unclear as of 2016, but it appeared to stimulate neurogenesis in rodents.